摘要
大约有四分之一的新药是蛋白类药物,其中糖蛋白药物占了绝大部分。本文从药物代谢动力学、组织靶向和调节生物活性等三个方面综述了糖基化对最佳治疗效果的影响,并且评估了CHO和酵母表达系统以求达到最佳糖基化。哺乳动物细胞培养是现今糖蛋白的生产系统,它存在以下几个缺点:成本高,周期长,糖基化作用受限。鉴于此,现在也已经开发了酵母表达系统来替代哺乳动物细胞培养,它具有表达能力高,发酵易于控制,可以进行氮糖基化的优点,尤其是P.pastoris工程酵母必将有更加广阔的应用前景。
Protein-based drugs constitute about a quarter of new approvals with a majority being glycoproteins. The purpose of this review is to highlight the influence of glycosylation on optimal therapeutic efficacy, and to evaluate the merits of expression systems to achieve optimal glycosylation. Mammalian cell culture, which is currently the production system of choice for glycoproteins,has several disadvantages including high cost of goods, long cycle times and, importantly, limited control over glycosylation. In view of this, yeast expression systems are currently being explored as alternatives to mammalian cell culture because they offer several advantages, such as robust expression, scalable fermentation, and the ability to perform. N-glycosylation, especially P. pastoris will have a better perspective in application.
出处
《安徽医药》
CAS
2008年第1期3-5,共3页
Anhui Medical and Pharmaceutical Journal
关键词
糖蛋白
糖基化
表达系统
glycoprotein
glycosylation
expression system
